Sano Genetics accelerates research into Long Covid after raising £2.5M ($3.2M) in seed funding
- Sano Genetics supports personalised medicine research by increasing participation in clinical trials and guiding patients through the process
- Half of clinical trials are delayed due to recruitment issues and 85% fail as they can’t retain enough participants1
- Seed round will fund free at-home DNA testing kits for 3,000 people affected by Long Covid, further development of its tech platform and team expansion
Cambridge, UK – Sano Genetics has raised £2.5M in seed funding led by Episode1 Ventures, alongside Seedcamp, Cambridge Enterprise, January Ventures, and several UK, Europe, and US-based angel investors.
Having raised £500K in a 2018 pre-seed round, the startup’s digital platform and at-home genetic testing capabilities are already empowering greater participation in crucial research into multiple sclerosis, ankylosing spondylitis, NAFLD, and ulcerative colitis, with a research programme for Parkinson’s disease on the agenda for later in 2021.
This latest funding round – coupled with a grant from Innovate UK – will cover the cost of free at-home DNA testing kits for 3,000 people affected by Long Covid, and the continued development of Sano Genetics’ ‘private-by-design’ tech platform, which gives users full control and transparency around how and where their personal data is used by researchers.
The company was co-founded in 2017 by Charlotte Guzzo, Patrick Short and William Jones who met at Cambridge University while studying genomics as postgrads. They observed, first hand, the high failure rate of clinical trials and the poor experiencefor those taking part.
Chief operating officer of Sano Genetics, Charlotte Guzzo, explains:
“We urgently need more people contributing to medical science, but the gap between those wanting to take part and actually knowing how to is huge. The scientific community has long relied on time-starved doctors signposting patients to clinical trials which just isn’t an effective way to get decent levels of participation. The pandemic has added further challenges, as many patients with rare and chronic diseases are unable to safely leave home.
“As such, the failure rate of clinical trials is shockingly high which has an enormous impact on patients with unmet medical needs, and financially hurts the companies investing in research. A technology-first, direct-to-patient approach has been long overdue.
“This tranche of funding will help us further develop the end-to-end experience for the many people keen to contribute to personalised medical research, including clinical trials of potentially life-changing medicines and, in doing so, improve the outlook for people living with chronic and often debilitating conditions.”
Sano Genetics has also partnered with Genomics England to develop software to be used by national-scale precision medicine initiatives and improve the participant experience in research. It will add an important layer of information reported directly by participants, such as daily symptom tracking, or via wearable devices that monitor activity or sleep.
Notes To Editor
Downloadable photos of co-founders, DNA kits and logos are available in our press kit.
About Sano Genetics
Based in Cambridge, UK, Sano Genetics helps people contribute to personalised medicine research effortlessly and on their terms. Its platform adopts innovations that are widespread in other sectors, including user-friendly digital interfaces, dynamic personalised feedback and an emphasis on data privacy, packaged as an end-to-end service that lets people power global studies from their own homes and guides them through the whole process. Crucially, users own their data and have full control over how it is used.